Who Owns Cardinal Health Nuclear & Precision Health Solutions?

• Parent Company: Cardinal Health
• Ownership Type: Brand division
• Company Type: Publicly Traded
• Stock Ticker: NYSE: CAH

• Founded: 2001
• Founders: Cardinal Health (internal development)

• Founded: 1971
• Headquarters: Dublin, Ohio, USA
• Company Type: Publicly Traded
• Stock: NYSE: CAH
• Revenue: approximately $226.0 billion (FY2025)
• Employees: Approximately 49,000

Visit Cardinal Health website

• Headquarters: Dublin, Ohio, USA
• Manufacturing / Operations: United States

Cardinal Health Nuclear & Precision Health Solutions operates within Cardinal Health's comprehensive healthcare sustainability framework, implementing environmental and ethical initiatives that align with the healthcare company's commitment to responsible radiopharmaceutical development and nuclear medicine practices. The division's Center for Theranostics Advancement in Indianapolis demonstrates leadership in sustainable precision medicine manufacturing and innovation.

Environmental Compliance and Safety: Cardinal Health Nuclear & Precision Health Solutions maintains strict adherence to Good Manufacturing Practices (GMP) regulations across all facilities. The division's facilities are designed with environmental control systems that ensure consistent and safe radiopharmaceutical production while minimizing environmental impact through advanced waste management and radiation safety protocols.

Sustainable Manufacturing Practices: The Commercial Manufacturing Center (CMC) within the Center for Theranostics Advancement implements sustainable manufacturing processes for theranostic radiopharmaceuticals. The facility supports the entire product lifecycle from development through commercial manufacturing at scale, emphasizing efficient resource utilization and minimal environmental footprint.

Radiation Safety and Environmental Protection: The division operates under strict Nuclear Regulatory Commission (NRC) licensing requirements, ensuring all facilities adhere to comprehensive radiation safety protocols. Cardinal Health Nuclear & Precision Health Solutions maintains advanced radiation protection systems and environmental monitoring to safeguard both workers and the community.

Precision Medicine Innovation Ethics: The division's theranostics development focuses on creating targeted treatments that may be less likely to harm healthy tissues than traditional treatments like radiation or chemotherapy. This precision approach demonstrates ethical commitment to patient safety while potentially offering better outcomes and quality of life.

Supply Chain Sustainability: Cardinal Health Nuclear & Precision Health Solutions operates the largest national network of nuclear pharmacies, enabling efficient distribution that minimizes transportation environmental impact. The division's strategic Indianapolis location allows reaching major U.S. population centers within 24 hours, optimizing logistics and reducing carbon footprint.

Community and Workforce Development: The Center for Theranostics Advancement was established in Indianapolis to leverage the region's strong pharmaceutical manufacturing workforce and experienced talent pool. The division contributes to local economic development while maintaining high standards for employee training and environmental stewardship.

Cardinal Health Nuclear & Precision Health Solutions has received significant recognition for its innovation in theranostics, leadership in nuclear medicine, and commitment to advancing precision medicine, establishing itself as a pioneer in the rapidly growing radiopharmaceutical industry.

Theranostics Innovation Leadership: The Center for Theranostics Advancement has been acknowledged as a groundbreaking facility bringing together dozens of innovators, scientists, and manufacturers developing theranostic radiopharmaceutical products. The division's ability to track approximately 60 high-probability theranostics innovations demonstrates industry leadership in precision medicine development.

Manufacturing Excellence Recognition: The Commercial Manufacturing Center has been recognized for connecting early-phase drug development with commercial manufacturing at scale. This integrated approach supports the entire product lifecycle from development through patient delivery, setting industry standards for comprehensive radiopharmaceutical services.

Regulatory Compliance Achievement: Cardinal Health Nuclear & Precision Health Solutions has been acknowledged for maintaining strict compliance with both FDA and NRC regulations. The division's adherence to Good Manufacturing Practices and radiation safety protocols has been recognized as demonstrating exceptional commitment to quality and safety.

Market Leadership Recognition: The division has been acknowledged as a leader in the rapidly growing theranostics market, which is expected to grow from $4.3 billion to $12.7 billion by 2029. Cardinal Health Nuclear & Precision Health Solutions' strategic positioning in this expanding market has been recognized as driving industry growth and innovation.

Unit Dose Service Excellence: For over 25 years, Cardinal Health Nuclear & Precision Health Solutions has been recognized as the leader in unit dose radiopharmaceuticals. The division's Total Solution™ approach has been acknowledged as providing comprehensive services that distinguish it from mere dose providers.

Geographic Strategic Advantage: The division's Indianapolis location has been recognized for providing strategic advantages in supporting the radiopharmaceutical industry. The facility's ability to reach major U.S. population centers within 24 hours and access to world-class courier hubs has been acknowledged as optimizing patient access to critical treatments.

Workforce Development Recognition: Cardinal Health Nuclear & Precision Health Solutions has been acknowledged for leveraging Indianapolis's experienced pharmaceutical manufacturing workforce and talent pool. The division's contribution to local economic development and workforce expertise has been recognized as strengthening the regional healthcare ecosystem.

Cardinal Health Nuclear & Precision Health Solutions has maintained a strong operational record within Cardinal Health's healthcare portfolio, though the division faces challenges typical of the highly regulated radiopharmaceutical industry and the emerging theranostics market.

Regulatory Compliance Complexity: Operating in the radiopharmaceutical industry requires compliance with dual regulatory oversight from both the FDA and NRC. Cardinal Health Nuclear & Precision Health Solutions must navigate complex regulatory requirements while maintaining innovation and rapid response to emerging medical needs.

Radiation Safety Management: Handling radioactive materials and radiopharmaceuticals presents inherent risks regarding radiation exposure and environmental safety. The division faces ongoing challenges in maintaining zero-tolerance safety standards while expanding operations and developing new therapeutic applications.

Supply Chain and Distribution Challenges: The time-sensitive nature of radiopharmaceuticals creates significant logistical challenges, as many products have very short half-lives and require specialized handling. Cardinal Health Nuclear & Precision Health Solutions must balance speed with safety and regulatory compliance across its national distribution network.

Market Competition and Innovation Pressure: The rapidly growing theranostics market attracts increasing competition from other pharmaceutical companies and specialized radiopharmaceutical manufacturers. Cardinal Health Nuclear & Precision Health Solutions faces pressure to maintain its leadership position while investing in innovation and infrastructure.

Technology Implementation Risks: The division's significant investments in advanced manufacturing technologies and theranostics development carry inherent risks regarding technological obsolescence and implementation challenges. Cardinal Health Nuclear & Precision Health Solutions must manage these investments while maintaining operational efficiency.

Healthcare Cost Management: While theranostics offer promise for better patient outcomes, the high cost of developing and manufacturing precision radiopharmaceuticals creates challenges regarding healthcare affordability and reimbursement. The division faces ongoing scrutiny regarding cost-effectiveness and value-based healthcare delivery.

Workforce Specialization Challenges: The highly technical nature of radiopharmaceutical manufacturing and theranostics development requires specialized expertise that is in limited supply. Cardinal Health Nuclear & Precision Health Solutions faces ongoing challenges in recruiting and retaining qualified nuclear pharmacists, radiopharmaceutical scientists, and regulatory specialists.

Environmental Impact Concerns: Despite strict regulatory compliance, the division's use of radioactive materials and specialized manufacturing processes faces ongoing scrutiny regarding environmental impact and community safety. Cardinal Health Nuclear & Precision Health Solutions must maintain transparent communication about safety measures and environmental stewardship.